We are live on ! Find out more
NTLA icon

Intellia Therapeutics
NTLA

290 hedge funds and large institutions have $3.19B invested in Intellia Therapeutics in 2023 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 108 increasing their positions, 73 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

48% more repeat investments, than reductions

Existing positions increased: 108 | Existing positions reduced: 73

9% more capital invested

Capital invested by funds: $2.93B → $3.19B (+$262M)

0% more funds holding

Funds holding: 290 → 290 (0)

0% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 34

0.64% less ownership

Funds ownership: 89.45% → 88.8% (-0.64%)

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

52% less call options, than puts

Call options by funds: $15.1M | Put options by funds: $31.5M

Holders
290
Holders Change
–
Holders Change %
0%
% of All Funds
4.55%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.09%
New
34
Increased
108
Reduced
73
Closed
34
Calls
$15.1M
Puts
$31.5M
Net Calls
-$16.4M
Net Calls Change
-$22.7M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$28.6M
2
Citadel Advisors
Citadel Advisors
Florida
+$17.7M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$12.3M
4
CIM
Contrarius Investment Management
Jersey
+$11.9M
5
NAMA
Nikko Asset Management Americas
New York
+$11.4M

Top Sellers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
-$58.5M
2
Bank of America
Bank of America
North Carolina
-$37.7M
3
N
Nuveen
North Carolina
-$22.6M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$14.2M
5
AIM
ARK Investment Management
Florida
-$12.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
LC
251
Lindbrook Capital
California
$7.22K +$3.73K +92 +108%
Fifth Third Bancorp
252
Fifth Third Bancorp
Ohio
$6.12K – – –
LF
253
Lee Financial
Texas
$5.59K – – –
GWS
254
Glassman Wealth Services
Virginia
$4.32K -$365 -9 -8%
SN
255
Sittner & Nelson
Oregon
$4.08K – – –
SWM
256
Spire Wealth Management
Virginia
$4.08K – – –
PIAS
257
PCA Investment Advisory Services
Ohio
$4.08K +$4.05K +100 New
BWM
258
Baystate Wealth Management
Massachusetts
$3.81K – – –
CTA
259
Colonial Trust Advisors
South Carolina
$3.06K – – –
SIS
260
Strategic Investment Solutions
Illinois
$2.86K – – –
GRP
261
Global Retirement Partners
California
$2.85K – – –
EWA
262
EverSource Wealth Advisors
Alabama
$2.69K +$2.68K +66 New
HPC
263
HM Payson & Co
Maine
$2.65K – – –
SHIM
264
Stone House Investment Management
Pennsylvania
$2.12K – – –
CMBA
265
C.M. Bidwell & Associates
Hawaii
$2.08K – – –
GEA
266
Glen Eagle Advisors
New Jersey
$2.04K – – –
CFGS
267
Concourse Financial Group Securities
Alabama
$1.83K – – –
VWM
268
Venturi Wealth Management
Texas
$1.75K -$608 -15 -26%
IA
269
IFP Advisors
Florida
$1.43K +$1.42K +35 New
QCG
270
Quadrant Capital Group
Ohio
$1.26K -$6.73K -166 -84%
HCM
271
Hollencrest Capital Management
California
$1.18K – – –
HWM
272
HighMark Wealth Management
Minnesota
$1.14K – – –
BHWM
273
Beaird Harris Wealth Management
Texas
$1.02K – – –
SIC
274
SJS Investment Consulting
Ohio
$1.02K – – –
NFSG
275
Newbridge Financial Services Group
Florida
$856 – – –
9 10
11
12 13

NTLA Hedge Fund Activity: Q2 2023 in Review

290 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2023, worth a combined $3.19B — up 9% from $2.93B a quarter earlier.

Fund positioning in NTLA was balanced in Q2 2023: 34 funds opened new positions, 34 closed out, 108 added to existing stakes and 73 trimmed.

The largest buyer was BlackRock, adding an estimated $28.6M. The largest seller was Viking Global Investors, exiting entirely with an estimated $58.5M sold.

  • 290 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $3.19B of Intellia Therapeutics stock for Q2 2023, up 9% quarter-over-quarter.
  • 34 funds opened new Intellia Therapeutics positions in Q2 2023 and 34 closed out, a net change of 0 holders.
  • The largest Intellia Therapeutics buyer in Q2 2023 was BlackRock, an estimated $28.6M added.
  • The largest Intellia Therapeutics seller in Q2 2023 was Viking Global Investors, an estimated $58.5M sold.

Based on aggregated 13F filings for Q2 2023.